This chapter offers a brief overview of some of the factors that have contributed to a rapid entry into the biotech and pharmaceutical company’s pipeline, focusing on how cell and gene therapies (CGT), collectively known as advanced therapies, have become the driving forces toward the therapeutic uses of gene editing technology.
The sum of all those efforts for more than 30 years has contributed to the new paradigm of considering genes as medicines.
The specific reference of this publication is as follows:
- Juan C. , Gene Editing and CRISPR Therapeutics: Strategies Taught by Cell and Gene Therapy. In: Raul Torres Ruiz, editors: CRISPR in Animals and Animal Models, Vol 152, Chennai: Academic Press; 2017, p. 115-130.
VIVEbiotech as an expert in the Gene Therapy field focused on Lentiviral vectors manufacture considers very relevant being deeply involved in the newest technologies in Gene Theraoy development.